A multi‐omics study to monitor senescence‐associated secretory phenotypes of Alzheimer's disease
Annals of Clinical and Translational Neurology · 2024
DOI: 10.1002/acn3.52047 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2024. Verfasst von Jingzhi Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Translational Medicine, Shanghai University, Shanghai, 200444, China. Hauptthemen laut MEDLINE: Alzheimer Disease, Biomarkers, Proteomics. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China.
Themen: Demenz
Abstract (Originalsprache)
Objective
Alzheimer's disease (AD) is characterized by the progressive degeneration and damage of neurons in the brain. However, developing an accurate diagnostic assay using blood samples remains a challenge in clinic practice. The aim of this study was to explore senescence‐associated secretory phenotypes (SASPs) in peripheral blood using mass spectrometry based multi‐omics approach and to establish diagnostic assays for AD.
Methods
This retrospective study included 88 participants, consisting of 29 AD patients and 59 cognitively normal (CN) individuals. Plasma and serum samples were examined using high‐resolution mass spectrometry to identify proteomic and metabolomic profiles. Receiver operating characteristic (ROC) analysis was employed to screen biomarkers with diagnostic potential. K‐nearest neighbors (KNN) algorithm was utilized to construct a multi‐dimensional model for distinguishing AD from CN.
Results
Proteomics analysis revealed upregulation of five plasma proteins in AD, including RNA helicase aquarius (AQR), zinc finger protein 587B (ZNF587B), C‐reactive protein (CRP), fibronectin (FN1), and serum amyloid A‐1 protein (SAA1), indicating their potential for AD classification. Interestingly, KNN‐based three‐dimensional model, comprising AQR, ZNF587B, and CRP, demonstrated its high accuracy in AD recognition, with evaluation possibilities of 0.941, 1.000, and 1.000 for the training, testing, and validation datasets, respectively. Besides, metabolomics analysis suggested elevated levels of serum phenylacetylglutamine (PAGIn) in AD.
Interpretation
The multi‐omics outcomes highlighted the significance of the SASPs, specifically AQR, ZNF587B, CRP, and PAGIn, in terms of their potential for diagnosing AD and suggested neuronal aging‐associated pathophysiology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Translational Medicine, Shanghai University, Shanghai, 200444, China.
- School of Medicine, Shanghai University, Shanghai, 200444, China.
- Department of Internal Medicine, Shanghai Baoshan Elderly Nursing Hospital, Shanghai, 200435, China.
- Neurology Department, Shanghai Baoshan Luodian Hospital, Shanghai, 201908, China.
- Department of Pharmacy, Shanghai Baoshan Luodian Hospital, Shanghai, 201908, China.
- Suzhou Innovation Center of Shanghai University, Suzhou, 215000, Jiangsu, China.
ORCID-Profile: Jingzhi Yang
Förderung
- National Key Research and Development Program of China
Zitieren
APA
Yang, J., Zhou, Y., Wang, T., Li, N., Chao, Y., Gao, S., Zhang, Q., Wu, S., Zhao, L., & Dong, X. (2024). A multi‐omics study to monitor senescence‐associated secretory phenotypes of Alzheimer's disease. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.52047
Vancouver
Yang J, Zhou Y, Wang T, Li N, Chao Y, Gao S, et al. A multi‐omics study to monitor senescence‐associated secretory phenotypes of Alzheimer's disease. Annals of Clinical and Translational Neurology. 2024. doi:10.1002/acn3.52047
BibTeX
@article{Yang2024,
author = {Yang, Jingzhi and Zhou, Yinge and Wang, Tianjiao and Li, Na and Chao, Yufan and Gao, Songyan and Zhang, Qun and Wu, Shuo and Zhao, Liang and Dong, Xin},
title = {A multi‐omics study to monitor senescence‐associated secretory phenotypes of Alzheimer's disease},
journal = {Annals of Clinical and Translational Neurology},
year = {2024},
doi = {10.1002/acn3.52047}
}
EUVIMED